A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.
about
VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuseVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryVesicular monoamine transporter 2: role as a novel target for drug developmentCadaverine's Functional Role in Plant Development and Environmental ResponseThe potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophyLobelane decreases methamphetamine self-administration in ratsDes-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transportersLobeline effects on tonic and methamphetamine-induced dopamine releaseThe effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in ratsDefunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporterComputational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2Offspring of Prenatal IV Nicotine Exposure Exhibit Increased Sensitivity to the Reinforcing Effects of MethamphetamineNicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Lobeline Effects on Cognitive Performance in Adult ADHD.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Pharmacological approaches to methamphetamine dependence: a focused review.Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin bindingRandomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine usePhenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2The twin drug approach for novel nicotinic acetylcholine receptor ligands.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine ToxicityThe effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2Morphine dependence and withdrawal induced changes in cholinergic signaling.Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivoGZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamineSex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.Methamphetamine-like discriminative-stimulus effects of nicotinic agonistsCholinergic functioning in stimulant addiction: implications for medications development.Lobeline attenuates neonatal ethanol-mediated changes in hyperactivity and dopamine transporter function in the prefrontal cortex in ratsPlant alkaloids that cause developmental defects through the disruption of cholinergic neurotransmission.Synthesis of Lobeline, Lobelane and their Analogues. A Review.
P2860
Q22242306-C0BA968C-C13D-486D-AB5A-5BA3AB092ABBQ24601233-80A45BF6-73A8-48F1-8F89-1EF217CEC607Q24647764-E11F1FDD-E747-4552-9E7E-1BD3C600D92AQ26742152-82608373-88F7-4FF3-9459-912BC50A995EQ26827638-196BE259-0779-4569-AFEE-E745B10BB7C4Q28235359-C38997DD-E142-4623-9817-76D225014DA3Q28257395-FDA3025D-8865-4FBE-929F-21D9DBD66AC6Q28264438-8BDE2257-FD57-4E1F-8234-546CFEDE752CQ28267531-386523B7-DF31-41BB-A73F-E338BF0FCAE6Q28267727-5D45946B-3FDE-407B-ADF4-E6085B32CAA4Q28290902-D9112480-50C4-4446-867F-C027A17A50B1Q30466480-E3A08DF4-92E3-484C-877D-55C1381A97C2Q30478324-D4FF0F3E-C3B4-43D6-B6EE-D87CBC4CF0F5Q30497495-84601DBF-12EC-4BE2-8AF9-F187A6B91F3AQ33613631-0A89C93A-98FA-4A7E-BC27-D617329399A3Q33738102-91F9B232-2B63-4A5D-B311-7FEE4128A155Q33774323-03038FBB-915F-4FB3-A50C-7D8FAC5154ABQ33854736-AA1DD5F7-CF06-4855-8C5F-9C43F5DE54CCQ33906303-C4977007-1239-4C3A-9A2E-8BD026B106BDQ34202539-28BB59D5-A84E-4DCC-8069-270471D1C5A8Q34262912-26E9D5C8-CFB6-4372-98C0-36885A7E6DE2Q34315501-168560C7-C674-424D-9B25-9BD3A32D37C5Q34702317-7AAECB7E-B5BC-4E8C-A7EC-3BC43D22A17DQ35682666-9AA54929-C186-4345-9D44-4C5D3968A033Q35810975-BC1FA540-7412-47A6-8F22-2C073F3A7DB8Q36079830-FD65E1E6-6CB1-492D-992D-C17F0F57072EQ36103932-DF7D84DE-FCD0-4504-AB03-67107219B8D1Q36949566-5E018F97-2599-48ED-8287-FEA80CAE5B40Q37052436-800B672B-3319-49B8-8505-E15C3A8D7E49Q37052442-BE397CF0-99B7-4707-BAAD-D02975C7EB60Q37052450-BCA373E4-19D0-4DBE-95C6-60E246042282Q37190441-E31DAAF8-4F50-4689-BC95-D4E31D3440ADQ37227997-E9D4F8EF-4EBA-49EC-A6EB-238C48EED9E7Q37292517-1199AB41-193F-4F2A-8863-B68316872E00Q37396979-2031477A-5439-43A8-A39E-331C173192B0Q37603896-140A5485-E00A-4663-9C08-9E9D031FA198Q37618780-8CFE0AF2-9BD0-4FF6-A1E9-F6C46E361038Q37718647-87C1C843-5701-425C-8220-E1FA076AFDE3Q38171428-83B8D04F-C99F-4ED1-93D7-A0F234408B09Q38267226-82487EB2-D7E1-4F1B-9DF4-4BDB16C4C20D
P2860
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A novel mechanism of action an ...... ent for psychostimulant abuse.
@ast
A novel mechanism of action an ...... ent for psychostimulant abuse.
@en
A novel mechanism of action an ...... ent for psychostimulant abuse.
@nl
type
label
A novel mechanism of action an ...... ent for psychostimulant abuse.
@ast
A novel mechanism of action an ...... ent for psychostimulant abuse.
@en
A novel mechanism of action an ...... ent for psychostimulant abuse.
@nl
prefLabel
A novel mechanism of action an ...... ent for psychostimulant abuse.
@ast
A novel mechanism of action an ...... ent for psychostimulant abuse.
@en
A novel mechanism of action an ...... ent for psychostimulant abuse.
@nl
P1476
A novel mechanism of action an ...... ent for psychostimulant abuse.
@en
P2093
Linda P Dwoskin
Peter A Crooks
P356
10.1016/S0006-2952(01)00899-1
P407
P577
2002-01-01T00:00:00Z